Bellevue Life Sciences Acquisition Corp. is a blank check company. It focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. Bellevue Life Sciences Acquisition Corp. is based in Bellevue, Washington.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-2.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.11 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -11549.51% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -6.66% |
| Return on Assets (Trailing 12 Months) | -4.90% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.20 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.35 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-3.87 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 25.67M |
| Free Float | 10.12M |
| Market Capitalization | $17.80M |
| Average Volume (Last 20 Days) | 11.03M |
| Beta (Past 60 Months) | 1.34 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 60.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 55.30% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |